AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward Medical Award Featured Site Award

IBS Tales Hope Award Editor's Choice Award

Listed in Listed in Treasures of the Internet

AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Revised October 14, 2017

Fact Sheet 432

Efavirenz (Sustiva, Stocrin)



Efavirenz is a drug used as part of antiretroviral therapy (ART). It is also called Sustiva or Stocrin. It is manufactured by Bristol-Myers Squibb. Generic versions are approved under PEPFAR (see fact sheet 925.)  Efavirenz is also part of the combination medication Atripla.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (a “non-nuke” or NNRTI). These drugs stop HIV from multiplying by preventing the reverse transcriptase enzyme from working. This enzyme changes HIV’s genetic material (RNA) into the form of DNA. This step has to occur before HIV’s genetic code gets inserted into an infected cell’s genetic codes.



Efavirenz was approved in 1998 as an antiretroviral drug (ARV) for people with HIV infection. It is not recommended for children under 3 months old.

While antiretroviral therapy (ART) is now recommended for all people living with HIV, there are no absolute rules about when to start ART. You and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking HIV medications. Fact Sheet 404 has more information about guidelines for the use of ARVs.

If you take efavirenz with other ARVs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.

Efavirenz seems to get into the central nervous system (spinal fluid). It may help prevent mental problems such as dementia.



Many new copies of HIV are mutations. They are slightly different from the original virus. Some mutations can keep multiplying even when you are taking an ARV. When this happens, the drug will stop working. This is called “developing resistance” to the drug. See Fact Sheet 126 for more information on resistance.

Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called “cross-resistance.” Cross-resistance among NNRTIs develops very easily. If you develop resistance to one NNRTI, you probably won’t be able to use any of them in your ART.

Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.



Efavirenz is taken by mouth as a capsule. The normal adult dose is 600 milligrams (mg) once a day at bedtime. Efavirenz is available in capsules of 50 mg, 100 mg, and 200 mg. 

It is recommended that you take efavirenz on an empty stomach, at bedtime. This dosing should result in the fewest side effects. High-fat foods increase efavirenz levels and should be avoided before taking a dose.



When you start any ART, you may have temporary side effects such as headaches, high blood pressure, or just feeling ill. These side effects usually get better or disappear within 2-4 weeks.

The most common side effects are fatigue (see fact sheet 551), rash, nausea, dizziness, diarrhea, headache and insomnia. Taking efavirenz with food increases drug levels and may increase side effects. Some people see changes in body fat (see fact sheet 553.)

To avoid dizziness after taking efavirenz, take it before you go to sleep. Some people have vivid dreams. For most people, these side effects disappear within the first two weeks of treatment.

About 5% of patients taking efavirenz had serious psychiatric symptoms. If you are taking efavirenz and experience serious depression, thoughts of suicide,  or other psychiatric symptoms, talk to your health care provider right away.

There have been a few reports of serious liver problems, even in people with no previous liver disease. Serious liver problems resulting in liver failure or death have been reported. Liver function tests should be done regularly, especially for people who have had hepatitis B or C or other liver problems. 

Studies in monkeys showed that efavirenz may cause birth defects. Pregnant women should avoid taking it, especially during the first 3 months of pregnancy. However, recent studies have shown no increase in birth defects in pregnant women taking efavirenz.

In the past, people who took efavirenz may falsely test positive for marijuana use. Current drug tests don't have this problem.



Efavirenz can interact with other drugs or supplements that you are taking. These interactions can change the amount of each drug in your bloodstream and cause an under- or overdose. New interactions are being identified all the time.

Drugs to watch out for include other ARVs, drugs to treat tuberculosis (see fact sheet 518), especially rifampin, which may require that you take a higher dose of efavirenz. Other drugs to watch out for include medications for erectile dysfunction (such as Viagra), for heart rhythm (antiarrhythmics), and for migraine headaches. Interactions are also possible with several antihistamines (allergy medications), sedatives, drugs to lower cholesterol, and anti-fungal drugs. Make sure that your health care provider knows about ALL drugs and supplements you are taking.

Efavirenz decreases blood levels of methadone. Efavirenz can lower concentrations of buprenorphine. 

The herb St. John's Wort (See Fact Sheet 729) lowers the blood levels of some nonnucleoside reverse transcriptase inhibitors. Do not take it with efavirenz.



Back to Fact Sheet Categories

International Association of Providers of AIDS Care


The AIDS InfoNet is a project of the International Association of Providers of AIDS Care.


United States National Library of Medicine

Partially funded by the National Library of Medicine

Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please click on the SUBMIT button.